[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, four-period, fully repeated crossover bioequivalence study of labetalol hydrochloride tablets (200 mg) in Chinese healthy subjects under fasting conditions

主要研究目的：按有关生物等效性试验的规定，选择Aspen Pharma Schweiz GmbH, Baar.为持证商的盐酸拉贝洛尔片（商品名：Trandate，规格：200mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂盐酸拉贝洛尔片（规格：200mg）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在空腹给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂盐酸拉贝洛尔片（规格：200mg）和参比制剂盐酸拉贝洛尔片（商品名：Trandate，规格：200mg）的安全性。

[Translation]

Main study purpose: According to the relevant provisions of bioequivalence test, labetalol hydrochloride tablets (trade name: Trandate, specification: 200 mg) of Aspen Pharma Schweiz GmbH, Baar. as the licensee were selected as the reference preparation, and the test preparation labetalol hydrochloride tablets (specification: 200 mg) produced and provided by Shijiazhuang Siyao Co., Ltd. were subjected to fasting human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation labetalol hydrochloride tablets (specification: 200 mg) and the reference preparation labetalol hydrochloride tablets (trade name: Trandate, specification: 200 mg) in healthy subjects.

Start Date01 Aug 2025

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

PACTR202504557828315

/ SuspendedPhase 4IIT

Intravenous Labetalol Versus Oral Nifedipine in The Control of Blood pressure in Severe Hypertensive disorders of Pregnancy: A Randomised Controlled Trial

Start Date01 Jul 2025

Sponsor / Collaborator-

CTR20250957

/ CompletedNot Applicable

盐酸拉贝洛尔片（200mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两制剂、两序列、四周期、完全重复交叉生物等效性试验

主要研究目的：按有关生物等效性试验的规定，选择Aspen Pharma Schweiz GmbH, Baar.为持证商的盐酸拉贝洛尔片（商品名：Trandate，规格：200mg）为参比制剂，对石家庄四药有限公司生产并提供的受试制剂盐酸拉贝洛尔片（规格：200mg）进行餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评价两种制剂在餐后给药条件下的生物等效性。次要研究目的：观察健康受试者口服受试制剂盐酸拉贝洛尔片（规格：200mg）和参比制剂盐酸拉贝洛尔片（商品名：Trandate，规格：200mg）的安全性。

[Translation]

Main study purpose: According to the relevant provisions of bioequivalence test, labetalol hydrochloride tablets (trade name: Trandate, specification: 200 mg) of Aspen Pharma Schweiz GmbH, Baar. as the licensee were selected as the reference preparation, and the test preparation labetalol hydrochloride tablets (specification: 200 mg) produced and provided by Shijiazhuang Siyao Co., Ltd. were subjected to human bioequivalence test after meal administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under the condition of postprandial administration. Secondary study purpose: To observe the safety of oral administration of the test preparation labetalol hydrochloride tablets (specification: 200 mg) and the reference preparation labetalol hydrochloride tablets (trade name: Trandate, specification: 200 mg) in healthy subjects.

Start Date07 Apr 2025

Sponsor / Collaborator

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

100 Clinical Results associated with Labetalol Hydrochloride

100 Translational Medicine associated with Labetalol Hydrochloride

100 Patents (Medical) associated with Labetalol Hydrochloride

3,605

Literatures (Medical) associated with Labetalol Hydrochloride

31 Dec 2025·Journal of Maternal-Fetal & Neonatal Medicine

Evaluation of fetal outcomes in dichorionic diamniotic twins with hypertensive disorders during pregnancy by the fetal middle cerebral artery and umbilical artery doppler

Article

Author: Lin, Xin ; Xu, Hai-hua ; Liu, Ling-ling

BACKGROUND:

Hypertensive disorders of pregnancy (HDP) is associated with the poor prognosis of dichorionic diamniotic (DCDA) twins. The prediction value of middle cerebral artery (MCA) and umbilical artery (UA) Doppler indices requires exploration.

OBJECTIVE:

To investigate the significance of the fetal MCA and UA doppler indices in DCDA fetal outcomes and depict hemodynamic alterations.

METHODS:

DCDA twin pregnancies were classified into the normotensive control group (n = 177) and the HDP group [n = 189, with 60 gestational hypertensions (GH) and 129 preeclampsia/eclampsia (PE/EC)]. Maternal and fetal outcomes were compared, the fetal MCA and UA doppler indices were analyzed, including pulsatility index (PI), resistance index (RI), the ratio of peak systolic blood flow velocity to end-diastolic blood flow velocity (S/D), and the mean velocities (Vm), and the cerebroplacental ratio (CPR) was computed for further study. The receiver operating characteristic curve was used to predict and evaluate small for gestational age (SGA) neonates in HDP twin pregnancies.

RESULTS:

Significant differences were shown between the HDP group and the normotensive control group in terms of maternal age, gestational weight gain, blood pressure, post 20-week urinary protein, the use of maternal medication utilization (magnesium sulfate, labetalol, dexamethasone), inter-twin growth discordance, and SGA (p < 0.05). In DCDA twins, the fetal MCA doppler indices (PI, RI and S/D) increased initially and then declined, UA indices (PI, RI and S/D) were declining, and both the Vm of MCA and UA were going up. In late DCDA twin pregnancies with GH, UA Doppler moderately predicted SGA neonates; in those with PE/EC, CPR did the same values (p < 0.05).

CONCLUSION:

In DCDA pregnancies complicated by hypertensive disorders, SGA twins exhibit distinct doppler deterioration patterns. Implementing customized monitoring strategies based on the fetal MCA and UA indices can effectively predict adverse conditions, enable timely interventions, and ensure fetal health.

01 Nov 2025·European Journal of Obstetrics & Gynecology and Reproductive Biology

Risk of postpartum readmission following discharge on nifedipine or labetalol for hypertensive disorders of pregnancy: A systematic review and meta-analysis

Review

Author: Ortiz, Vanessa ; Kanninen, Tomi ; Haddad, Andrew ; Alvarez, Manuel ; Al-Khan, Abdulla ; Alvarez-Perez, Jesus

OBJECTIVES:

To examine if the postpartum readmission rate was influenced by the use of nifedipine compared with labetalol at discharge in patients with hypertensive disorders of pregnancy.

STUDY DESIGN:

PubMed, ClinicalTrials.gov, Science Direct and the Cochrane Central Register of Controlled Trials were searched from inception to September 2024.All studies comparing the readmission rate following use of nifedipine vs labetalol after postpartum discharge in patients with hypertensive disorders of pregnancy were identified. Risk of bias was assessed according to the Newcastle-Ottawa Scale.

RESULTS:

Four studies were identified, representing 13,628 patients in the nifedipine group and 23,348 patients in the labetalol group. Study quality was judged to be good. The readmission rate was significantly lower when patients were discharged on nifedipine compared with labetalol [RR 0.41, 95% confidence interval (CI) 0.33-0.52]. Furthermore, the readmission rate specifically for hypertensive complications was significantly lower in patients discharged on nifedipine compared with labetalol (RR 0.36, 95% CI 0.23-0.56). The readmission rate for all causes did not differ significantly between patients discharged on nifedipine compared with labetalol (RR 0.69, 95% CI 0.33-1.43). Robustness of these findings were confirmed through sensitivity analysis.

CONCLUSION:

Discharge on nifedipine for management of hypertensive disorders of pregnancy was associated with a significantly lower readmission rate for hypertensive complications compared with discharge on labetalol.

01 Oct 2025·JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY

Differences in Outcomes for Patients Receiving Labetalol and Nicardipine for Hypertension After Craniotomy

Article

Author: Torjman, Marc ; Sun, George ; Min, Kevin J. ; Owrey, Matthew

Background::

Acute postoperative hypertension (APH) is encountered in patients following craniotomy and is associated with major complications. This retrospective cohort study evaluates 30-day survival for patients who received labetalol, nicardipine, or both drugs.

Methods::

Patients 18 and older who underwent craniotomy between January 1, 2010 and January 1, 2023 were included in the study. Analyses were performed comparing (1) labetalol cohort versus nicardipine cohort, (2) labetalol cohort versus both cohort, and (3) nicardipine cohort versus both cohort. The primary outcome was survival at 30 days. Secondary outcomes included 30-day readmission, ST-elevation myocardial infarction (STEMI), congestive heart failure (CHF), non-ST elevation myocardial infarction (NSTEMI), arrhythmia, and intracranial hemorrhage.

Results::

The labetalol cohort had improved 30-day survival compared with the nicardipine cohort (HR: 0.49, P<0.0001) or both (HR: 0.67, P<0.0001). The nicardipine cohort had worse survival compared with both cohorts (HR: 1.28, P<0.0001). The labetalol cohort had a lower risk of intracranial hemorrhage compared with nicardipine (RR: 0.89, P=0.001) and both cohorts (RR: 0.90, P<0.001). The labetalol cohort had less congestive heart failure than the nicardipine cohort (RR: 0.66, P<0.0001), and the nicardipine cohort had more CHF than the cohort that received both drugs (RR: 1.21, P=0.018). There was no difference in STEMI, NSTEMI, or readmissions across cohorts.

Conclusions::

Labetalol for APH after craniotomy is associated with improved survival compared with nicardipine or combination. A combination of these drugs is associated with improved survival compared with nicardipine alone.

News (Medical) associated with Labetalol Hydrochloride

29 Aug 2025

·www.einpresswire.com

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

03 Sep 2024

·www.pharmaceutical-technology.com

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

At the ESC Congress, Dr. Milton Packer highlighted recent research into beta blocker treatment for myocardial infarction. Credit: luchschenF via Shutterstock. A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at the European Society of Cardiology (ESC) Congress, held from 31 August to 2 September. Over the past 40 years, the research space has operated on an understanding that immediate inhibition by beta-blockers reduces left ventricular rupture, and further myocardial infarction , said Dr. Milton Packer, distinguished scholar in cardiovascular science at Baylor University Medical Center, Dallas. Additionally, the belief was that delayed long-term blockade can lead to left ventricular dysfunction, he said. Beta-blockers are a class of drugs that act by inhibiting the actions of hormones such as adrenaline to slow down the heart. Commonly used beta blockers include Abbott ’s Tenormin (atenolol), MSD’s Cardicor (bisoprolol), and GSK ’s Trandate (labetalol). However, Packer explained that the beta blocker response has changed as percutaneous interventions, reperfusion therapies, antiplatelet drugs and more have entered the treatment landscape for myocardial infarction. At the ongoing ESC Congress talk titled “Should we give beta blockers post-myocardial infarction?” Packer said that questions have been raised surrounding the use of the drugs in patients with myocardial infarction and preserved ejection fraction, referencing the Phase IIII REDUCE-AMI study (NCT03278509). See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication REDUCE-AMI, which was funded by the Swedish Research Council, tested the use of beta-blockers after myocardial infarction and preserved ejection fraction. The study found that for patients with acute myocardial infarction who underwent early coronary angiography and had preserved left ventricular ejection fraction, long-term beta-blocker treatment did not lower the risk of death from any cause or new myocardial infarctions compared to no beta-blocker use. Despite the conclusion of the REDUCE-AMI study, Packer highlighted the fact that researchers have only investigated and proven the effectiveness of non-selective beta blockers in post-myocardial infarction trials, so further research is required. He added that physicians will have to take into account the degree of beta-blockade in future treatment regimens.

VaccinePhase 3Drug ApprovalClinical Result

17 Jun 2024

·www.drugs.com

2008 to 2021 Saw Increase in Prevalence of Chronic HTN in Pregnancy

MONDAY, June 17, 2024 -- For pregnant individuals, the prevalence of chronic hypertension more than doubled between 2008 and 2021, according to a study published online June 17 in Hypertension . Stephanie A. Leonard, Ph.D., from the Stanford University School of Medicine in California, and colleagues analyzed commercial insurance claims from 2007 to 2021 and assessed the prevalence of chronic hypertension during pregnancy and trends in oral antihypertensive medication use. The researchers found that between 2008 and 2021, the prevalence of chronic hypertension increased steadily from 1.8 to 3.7 percent among 1,900,196 pregnancies. During the study period, antihypertensive medication use among those with chronic hypertension was relatively stable (57 to 60 percent). There was a decrease seen in the proportion of pregnant individuals with chronic hypertension treated with methyldopa or hydrochlorothiazide (from 29 to 2 percent and from 11 to 5 percent, respectively), and there was an increase seen in the proportion treated with labetalol or nifedipine (from 19 to 42 percent and from 9 to 17 percent, respectively). Following the 2017 American College of Cardiology and American Heart Association hypertension guidelines, there was no change observed in the prevalence or treatment of chronic hypertension during pregnancy. "There were large shifts in the medications used to treat chronic hypertension in pregnancy, with labetalol supplanting methyldopa as the most commonly used antihypertensive medication," the authors write. One author disclosed ties to the pharmaceutical industry.

AHAClinical Study

100 Deals associated with Labetalol Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00600	Labetalol Hydrochloride	C07AG01	DB00598

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	Schering Corp.	01 Aug 1984
Hypertension	United States	Alvogen, Inc.	01 Aug 1984
Essential Hypertension	Japan	Sandoz AG	07 Oct 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04343235 (CTgov)	Phase 4	Hypertension, Pregnancy-Induced \| Pre-Eclampsia	13	labetalol+furosemide (Labetalol + Furosemide)	zkfwvdkwfa = xwtpuxqbhb bvjvzcvmle (eoucgfyqor, kjzoakqimk - wywtwjepyv) View more	-	23 Oct 2023
				labetalol (Labetalol Only)	zkfwvdkwfa = pkuhqzesmp bvjvzcvmle (eoucgfyqor, yhismggmqb - dpzpxqltrh) View more
NCT04116112 (BEST-II, CTgov)	Phase 2	Thrombosis \| Stroke	120	Labetalol+Nicardipine+Hydralazine (Higher Systolic Blood Pressure (SBP) Target)	hsgzhdgpjc(aettwizfpq) = xuiuxwawfd bbbqklkcnt (cuczllvxwg, eyonbwtizj - uzcimkgpjp) View more	-	12 Oct 2023
				Labetalol+Nicardipine+Hydralazine (Lower SBP (<160 mmHg) Target)	hsgzhdgpjc(aettwizfpq) = bzfqdsjxjt bbbqklkcnt (cuczllvxwg, kwruxdnebf - nlgbgxcccz) View more
NCT04539379 (ZU-IRB#: 6353-23-3-2020, Pubmed \| J Clin Monit Comput)	Not Applicable	Pre-Eclampsia	-	Magnesium sulfate	iltsclxkmq(zrnakgjztm) = lmaoivieqr kjtmfoaqgk (lwwnwftjra )	Positive	01 Aug 2023
				Labetalol	iltsclxkmq(zrnakgjztm) = reakrwresa kjtmfoaqgk (lwwnwftjra )
NCT03506724 (CTgov)	Phase 4	Pre-Eclampsia	109	Labetalol (Intravenous Labetalol)	tezkacjsfh(cchlsgayrs) = rozffxqfvv zsrszcbcic (amtgeproal, nkoxrtexnu - bnbzkqmxoa) View more	-	24 May 2021
				Nifedipine (Oral Nifedipine)	tezkacjsfh(cchlsgayrs) = brszcobhco zsrszcbcic (amtgeproal, ywqfvogcrn - viqhrwzvcl) View more
NCT01114971 (CTgov)	Phase 4	Pain, Postoperative	75	Esmolol+Labetalol (Fentanyl)	siialjdvkl(lqxhifdmrv) = cngnnggdbr zyvhddkuuv (venebbkuzc, 2) View more	-	20 Feb 2020
				Fentanyl+Esmolol (Labetalol)	siialjdvkl(lqxhifdmrv) = xnhvsvefwz zyvhddkuuv (venebbkuzc, 3) View more
NCT02168309 (CTgov)	Not Applicable	Hypertension	50	Labetalol (Labetalol)	zmsblixirs(khrmyodptf) = xafzsxlepx myuvkolxtp (wsbewdltit, 32.5) View more	-	13 Dec 2017
				Nifedipine (Nifedipine)	zmsblixirs(khrmyodptf) = mctpsgxtrr myuvkolxtp (wsbewdltit, 27.6) View more
ISRCTN40973936 (Pubmed \| Hypertension)	Not Applicable	Hypertension, Pregnancy-Induced First line	112	Labetalol	wnevlbpsxp(zktpnrghvi) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis agyesmivso (qggkjqwqth )	-	01 Nov 2017
				Nifedipine-modified release
NCT02168309 (Pubmed \| Hypertens Pregnancy)	Not Applicable	Hypertension	50	Oral labetalol	stgfqghywc(rbrrueadyl) = szjwbqwnvz wppqnrlzps (kwjrllvnbs )	-	02 Jan 2017
				Oral extended release nifedipine	stgfqghywc(rbrrueadyl) = binvarvkcj wppqnrlzps (kwjrllvnbs )
NCT00765648 (CLUE, CTgov)	Phase 4	Hypertension	226	Nicardipine (Nicardipine)	yeiepcvrni = qdaxcwraaw mokswbrcdi (qfbjcqsqkz, rjadziibzm - nxxmjrnbmn) View more	-	11 Dec 2014
				Labetalol (Labetalol)	yeiepcvrni = nfaiwzvbcz mokswbrcdi (qfbjcqsqkz, pafziszsmv - lsxixwrgpa) View more
NCT01041066 (Pubmed \| Clin Ther)	Not Applicable	Hypertension	130	Nicardipine 20 μg/kg IV	pliapmmttp(apawezmhqq) = qrbphxaqds eezuvzdepv (kneesxatkn )	-	01 Mar 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Labetalol Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation